Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Operating Expenses (2022 - 2024)

Taysha Gene Therapies' Other Operating Expenses history spans 3 years, with the latest figure at $4.8 million for Q3 2024.

  • For Q3 2024, Other Operating Expenses rose 685.39% year-over-year to $4.8 million; the TTM value through Jun 2025 reached $4.8 million, down 94.08%, while the annual FY2024 figure was $4.8 million, 94.08% down from the prior year.
  • Other Operating Expenses for Q3 2024 was $4.8 million at Taysha Gene Therapies, down from $81.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $81.2 million in Q4 2023 and bottomed at $388000.0 in Q2 2022.
  • The 3-year median for Other Operating Expenses is $4.8 million (2024), against an average of $24.7 million.
  • The largest annual shift saw Other Operating Expenses soared 122.88% in 2023 before it surged 685.39% in 2024.
  • A 3-year view of Other Operating Expenses shows it stood at $36.4 million in 2022, then surged by 122.88% to $81.2 million in 2023, then tumbled by 94.04% to $4.8 million in 2024.
  • Per Business Quant, the three most recent readings for TSHA's Other Operating Expenses are $4.8 million (Q3 2024), $81.2 million (Q4 2023), and $616000.0 (Q3 2023).